T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-03-01 / J Immunother Cancer 2020 03;8(1)Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-27 / Cancers (Basel) 2020 Feb;12(3)Immunotherapy in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-21 / Front Oncol 2020;10:187Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
/in Dendritic Cells, International Publications /von 2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
/in Dendritic Cells, International Publications /von 2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma, Newcastle Disease Virus /von 2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-01 / J Immunother Cancer 2020 02;8(1)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de